A three-peptide blend of BPC-157, TB-500 and GHK-Cu, pairing the two repair peptides with the copper-binding tripeptide studied around skin and connective tissue.
Coming soon
You are on the list. We will email you if Glow becomes available — and nothing else. Joining is not a medical request, and no prescription has been issued.
That did not go through. Check the address and try again.
Glow is not available yet. Adding your email tells us to prioritize it, and any future treatment would still go through a licensed provider.
How it works once Glow is available
Every treatment gets its own online clinical questionnaire — your history, medications, and goals.
A clinician reads your history and takes the time to get it right before anything is prescribed.
Compounded for your prescription and shipped cold-chain, with care-team check-ins after.
Glow is easy to find online and hard to trust there. Promise works the way medicine is supposed to work — a clinician decides, a licensed pharmacy fills, and someone stays accountable to you.
Prescribed for you specifically, after a real look at your health history — never pulled off a shelf.
Your prescription is compounded for you by a licensed U.S. pharmacy — not a mystery vial from an unregulated website.
Temperature-safe shipping, follow-up check-ins, and a care team that answers — before and after your medication arrives.
BPC-157 and TB-500 are the repair peptides already prescribed together as Wolverine. Glow would add GHK-Cu, the copper-binding tripeptide studied around connective tissue.
Wolverine is the pair on its own; KLOW adds both KPV and GHK-Cu. Glow sits between them, with the connective-tissue component and without KPV.
Glow cannot be prescribed through Promise today. If it becomes available, a licensed provider would read your history and decide.
Glow is not available through Promise yet. There is no intake questionnaire for it, no price, and no date we are prepared to commit to. This page exists so the compound can be described honestly, and so the people who want it can tell us.
What Glow would be is a three-peptide blend in a single compounded vial: BPC-157, TB-500 and GHK-Cu. Two of those are the repair peptides already prescribed together as Wolverine. The third is the copper-binding tripeptide we offer on its own as GHK-Cu.
BPC-157 is a synthetic peptide based on a sequence identified in human gastric juice. Research interest in it centers on tissue-repair signaling and on angiogenesis — the formation of new small blood vessels. TB-500 is a synthetic fragment of thymosin beta-4, a protein involved in actin regulation and cell migration, studied in that same repair context from a different angle.
GHK-Cu is the outlier of the three. It is a naturally occurring tripeptide that binds a copper ion, circulates in human plasma at concentrations that fall as a person ages, and has been studied for its role in extracellular-matrix remodeling — the collagen and elastin scaffolding that holds skin and connective tissue together.
Put that together and the reasoning behind the blend is legible: two compounds studied around repair signaling, one studied around the material the body repairs with. That is a rationale. It is not a result.
We already prescribe two blends in muscle and recovery. Wolverine is the pair — BPC-157 and TB-500, nothing else. KLOW is the wider formulation, adding KPV and GHK-Cu on top of that pair.
Glow would be the step between them: the Wolverine pair with GHK-Cu added, and without KPV. For someone whose provider wants the connective-tissue component but has no particular reason to include KPV, that is a cleaner fit than either blend we currently offer. Filling that gap is the whole argument for building it.
None of this is a ranking. A wider blend is not a stronger one, and a narrower blend is not a beginner's version. Which formulation suits a person is a clinical judgment about their history and their other medications.
It is worth being clear-eyed here. The published work on BPC-157 and TB-500 is overwhelmingly preclinical — animal models and laboratory studies — with very little controlled human data behind it. GHK-Cu has a longer dermatology literature, but most of that concerns topical formulations rather than a compounded injectable.
A blend inherits every one of those limits and adds one of its own: three compounds studied separately have not been studied much together. Combining them is a clinical decision made about a particular person, not a conclusion the literature has already reached.
We would rather set that out plainly on a page nobody can act on yet than let it go unsaid on a page they can.
Every treatment here needs three things before it goes live: a pharmacy willing to compound it, a clinical intake questionnaire written specifically for it, and a provider network willing to prescribe it. Glow does not have that set assembled.
So we are not taking requests for it, and we will not guess at a date. The waitlist does one job — it tells us whether the demand justifies the work of building it. If it does, this page changes. If it does not, it stays as it is.
If Glow launches, it would work the way everything else here works. You would complete an intake questionnaire built for this specific formulation, covering your health history, current medications, and what you are trying to address. A licensed provider would read it and prescribe only if Glow were appropriate for you.
If it were prescribed, it would be compounded and dispensed by a licensed U.S. pharmacy, and shipped in temperature-safe packaging, with follow-up check-ins from your care team. Until that day, the honest answer is that this one is not ready — and saying so is part of how we keep our own promises.
Glow is a proposed three-peptide blend: BPC-157, TB-500 and GHK-Cu in a single compounded vial. BPC-157 and TB-500 are the two peptides research most often reads as repair-signaling compounds, and they are already prescribed together as Wolverine. GHK-Cu is a naturally occurring copper-binding tripeptide studied for its role in extracellular-matrix remodeling — the collagen and elastin scaffolding of skin and connective tissue. Glow is not available through Promise yet.
We do not have a date, and we are not willing to invent one. We are not taking requests for Glow, and there is no intake questionnaire for it. Before any treatment goes live here it needs a pharmacy that will compound it, a clinical intake written specifically for it, and a provider network willing to prescribe it. The waitlist is simply how we measure whether the demand justifies assembling that.
No. Glow is not FDA-approved. It would be prepared as a compounded medication, and compounded medications are not reviewed by the FDA for safety, effectiveness, or quality. Nor is it available at present — nothing about this page should be read as an offer to treat.
Wolverine is BPC-157 and TB-500 together, and nothing else. KLOW is the wider formulation, adding KPV and GHK-Cu on top of that pair. Glow would be the step between them — the Wolverine pair with GHK-Cu added, without KPV. A wider blend is not a stronger one and a narrower blend is not a starter version; which formulation suits a person is a clinical judgment about their history, not a tier they select.
Yes. Everything Promise offers is prescription-only, and Glow would be no exception. You would complete an intake questionnaire written for this specific formulation, a licensed provider would review your health history and medications, and they would prescribe only if Glow were appropriate for you.
Other Muscle & Recovery options a provider may consider.
Muscle & Recovery
BPC-157 + TB-500 — the classic two-peptide recovery pairing, prescribed as one blend.
Requires an online medical evaluation. Prescribed only when a licensed provider determines it's appropriate.
Muscle & Recovery
Four-peptide blend — BPC-157, GHK-Cu, KPV, TB-500 — studied for tissue repair, skin, and recovery support.
Requires an online medical evaluation. Prescribed only when a licensed provider determines it's appropriate.
Muscle & Recovery
A synthetic fragment of thymosin beta-4, studied for cell-migration signaling and the tissue-repair processes involved in recovery.
Requires an online medical evaluation. Prescribed only when a licensed provider determines it's appropriate.